Canadian Regulatory Context BPC-157 has not been approved for human medical use by Health Canada or any other major regulatory body, including the U.S
By suppressing TGF-1 expression and preventing Smad2/3 phosphorylation, luteolin downregulates core ECM components, such as collagen I, fibronectin, and alpha-smooth muscle actin (-SMA), thereby limiting myofibroblast activation and pathological ECM accumulation
This had no impact on the peer review process and the final decision
Most searches for segulatide are misspellings of semaglutide
Results from injectable protocols are typically visible within 4 to 8 weeks with consistent use, and the changes reflect actual shifts in collagen density, skin thickness, and cellular repair activity rather than surface conditioning
Despite a recommended daily intake as low as 6 micrograms, B12 deficiency remains common, particularly among individuals following vegan or vegetarian diets